Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Long-term Activity Ratios (Summary)

Abiomed Inc., long-term (investment) activity ratios

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Net fixed asset turnover 5.10 4.30 5.10 5.31 5.07 5.07
Net fixed asset turnover (including operating lease, right-of-use asset) 4.87 4.17 4.76 5.31 5.07 5.07
Total asset turnover 0.62 0.57 0.69 0.73 0.76 0.81
Equity turnover 0.69 0.64 0.79 0.82 0.86 0.99

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The analysis of long-term activity ratios between 2017 and 2022 reveals a general decline in overall asset and equity utilization efficiency, contrasted by relative stability in fixed asset productivity.

Fixed Asset Efficiency
Net fixed asset turnover remained relatively stable throughout the period, fluctuating within a narrow range between 4.30 and 5.31. A peak in efficiency was recorded in 2019 at 5.31, followed by a significant dip to 4.30 in 2021, before recovering to 5.10 in 2022. When right-of-use assets from operating leases are included, the ratio follows a similar trajectory but consistently remains lower from 2020 onward, reaching a minimum of 4.17 in 2021. This suggests that while core fixed asset utilization is consistent, the integration of lease assets has slightly lowered the overall turnover ratio for this category.
Overall Asset Utilization
Total asset turnover exhibits a sustained downward trend for the majority of the period, decreasing from 0.81 in 2017 to a low of 0.57 in 2021. Despite a slight rebound to 0.62 in 2022, the overall decline indicates that the growth in the company's total asset base has outpaced the growth in revenue generation.
Equity Turnover
Equity turnover demonstrates a pattern closely mirroring total asset turnover, declining from 0.99 in 2017 to 0.64 in 2021, followed by a modest increase to 0.69 in 2022. This trend indicates a reduction in the efficiency of generating revenue relative to the amount of equity invested in the company over the observed timeframe.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Net Fixed Asset Turnover

Abiomed Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
Property and equipment, net 202,490 197,129 164,931 145,005 117,167 87,777
Long-term Activity Ratio
Net fixed asset turnover1 5.10 4.30 5.10 5.31 5.07 5.07
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 4.76 4.81 — — — —
Elevance Health Inc. 36.07 34.94 — — — —
Intuitive Surgical Inc. 2.62 3.04 — — — —
Medtronic PLC 5.85 5.77 — — — —
UnitedHealth Group Inc. 31.81 31.81 — — — —
Net Fixed Asset Turnover, Sector
Health Care Equipment & Services 17.82 17.31 — — — —
Net Fixed Asset Turnover, Industry
Health Care 7.88 7.74 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 1,031,753 ÷ 202,490 = 5.10

2 Click competitor name to see calculations.


The financial trajectory from 2017 to 2022 is characterized by consistent growth in both top-line revenue and the investment in fixed assets. Revenue increased from 445.3 million US dollars in 2017 to over 1.03 billion US dollars by 2022, while net property and equipment expanded from 87.8 million US dollars to 202.5 million US dollars over the same period.

Net Fixed Asset Turnover Stability
The net fixed asset turnover ratio remained relatively stable for the majority of the analyzed period, oscillating primarily around the 5.10 mark. This consistency indicates a strategic alignment between the acquisition of long-term assets and the generation of sales.
Efficiency Variance
A peak in asset utilization efficiency was observed in 2019, reaching a ratio of 5.31. This was followed by a gradual decline, culminating in a low of 4.30 in 2021. The dip in 2021 suggests a period where the growth of the net fixed asset base outpaced the growth in revenue, leading to a temporary decrease in asset productivity.
Operational Recovery
A recovery to a ratio of 5.10 occurred by March 31, 2022. This return to previous efficiency levels was driven by a significant acceleration in revenue, which reached 1.03 billion US dollars, effectively absorbing the increased investment in property and equipment.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Abiomed Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
 
Property and equipment, net 202,490 197,129 164,931 145,005 117,167 87,777
Operating lease right-of-use assets 9,518 6,109 11,760 — — —
Property and equipment, net (including operating lease, right-of-use asset) 212,008 203,238 176,691 145,005 117,167 87,777
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 4.87 4.17 4.76 5.31 5.07 5.07
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Abbott Laboratories 4.25 4.26 — — — —
Elevance Health Inc. 31.64 30.12 — — — —
Intuitive Surgical Inc. 2.53 2.93 — — — —
Medtronic PLC 5.06 4.84 — — — —
UnitedHealth Group Inc. 21.54 21.54 — — — —
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Health Care Equipment & Services 14.39 13.89 — — — —
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 6.90 6.75 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 1,031,753 ÷ 212,008 = 4.87

2 Click competitor name to see calculations.


Between March 31, 2017, and March 31, 2022, a consistent upward trajectory in both revenue and net fixed assets was observed. Revenue grew from 445.3 million US dollars to over 1.03 billion US dollars, while net property and equipment, including right-of-use assets, increased from 87.8 million US dollars to 212.0 million US dollars. This simultaneous growth indicates a strategic expansion of the company's operational infrastructure to support increasing sales volumes.

Revenue Generation and Asset Scaling
Revenue experienced a strong growth trend, specifically accelerating between 2017 and 2019 and again in 2022. During the same period, investments in property and equipment grew steadily each year. The expansion of the asset base suggests a continuous commitment to increasing production capacity or expanding operational footprints.
Net Fixed Asset Turnover Volatility
The net fixed asset turnover ratio exhibited fluctuations, peaking at 5.31 in 2019 before declining to a low of 4.17 in 2021. This decline indicates a period where the growth in fixed asset investment outpaced the growth in revenue, potentially reflecting a phase of heavy capital expenditure in anticipation of future demand.
Efficiency Recovery
A recovery in asset efficiency occurred by March 31, 2022, with the turnover ratio rising to 4.87. This improvement is attributed to a significant surge in revenue, which reached 1.03 billion US dollars, effectively leveraging the previously expanded asset base to generate higher output per unit of investment.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Total Asset Turnover

Abiomed Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
Total assets 1,673,393 1,494,359 1,216,462 1,054,346 786,375 550,414
Long-term Activity Ratio
Total asset turnover1 0.62 0.57 0.69 0.73 0.76 0.81
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.59 0.57 — — — —
Elevance Health Inc. 1.51 1.41 — — — —
Intuitive Surgical Inc. 0.48 0.42 — — — —
Medtronic PLC 0.35 0.32 — — — —
UnitedHealth Group Inc. 1.31 1.34 — — — —
Total Asset Turnover, Sector
Health Care Equipment & Services 1.06 1.02 — — — —
Total Asset Turnover, Industry
Health Care 0.66 0.62 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Total asset turnover = Revenue ÷ Total assets
= 1,031,753 ÷ 1,673,393 = 0.62

2 Click competitor name to see calculations.


An analysis of the financial performance between March 31, 2017, and March 31, 2022, reveals a period of substantial expansion in both top-line revenue and the total asset base, accompanied by a general decline in asset utilization efficiency.

Revenue Growth Trends
Revenue exhibited a strong upward trajectory, increasing from 445,304 thousand US$ in 2017 to 1,031,753 thousand US$ in 2022. While growth was particularly aggressive between 2017 and 2020, a period of relative stagnation occurred between 2020 and 2021, before revenue surged past the one-billion-dollar threshold in 2022.
Asset Base Expansion
Total assets grew consistently and rapidly throughout the analyzed period, rising from 550,414 thousand US$ in 2017 to 1,673,393 thousand US$ in 2022. The growth in assets was persistent and linear, indicating a significant and continuous investment in the company's infrastructure or resource base.
Total Asset Turnover Analysis
The total asset turnover ratio experienced a steady downward trend for the majority of the period, falling from 0.81 in 2017 to a low of 0.57 in 2021. This decline indicates that the growth in the asset base outpaced the growth in revenue, leading to a decrease in the efficiency with which assets were used to generate sales. A slight recovery was observed in 2022, with the ratio increasing to 0.62, correlating with the accelerated revenue growth in the final year.

Overall, the data suggests a strategic phase of heavy investment where asset accumulation grew faster than corresponding revenue gains, resulting in a lower turnover ratio over time, despite the significant absolute increase in annual sales.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Equity Turnover

Abiomed Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
Stockholders’ equity 1,503,326 1,329,675 1,065,466 936,890 689,524 452,071
Long-term Activity Ratio
Equity turnover1 0.69 0.64 0.79 0.82 0.86 0.99
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 1.19 1.20 — — — —
Elevance Health Inc. 4.29 3.80 — — — —
Intuitive Surgical Inc. 0.56 0.48 — — — —
Medtronic PLC 0.60 0.59 — — — —
UnitedHealth Group Inc. 4.14 3.98 — — — —
Equity Turnover, Sector
Health Care Equipment & Services 2.61 2.42 — — — —
Equity Turnover, Industry
Health Care 1.69 1.67 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Equity turnover = Revenue ÷ Stockholders’ equity
= 1,031,753 ÷ 1,503,326 = 0.69

2 Click competitor name to see calculations.


A comprehensive review of the investment activity ratios reveals a persistent divergence between revenue growth and the expansion of stockholders' equity over the six-year period ending March 31, 2022. While both metrics exhibit strong upward trajectories, the rate of capital accumulation has consistently exceeded the rate of sales expansion for the majority of the period, leading to a general decline in equity efficiency.

Revenue Trends
Revenue demonstrated a consistent and significant upward trajectory, increasing from US$ 445.3 million in 2017 to US$ 1.03 billion in 2022. The most substantial growth occurred between 2017 and 2019, followed by a period of stabilization before accelerating again in the final year of the analysis.
Stockholders' Equity Expansion
The equity base grew rapidly and without interruption, rising from US$ 452.1 million in 2017 to US$ 1.50 billion in 2022. This growth suggests a strong internal capital accumulation or significant retained earnings, as the equity base more than tripled over the observed timeframe.
Equity Turnover Analysis
The equity turnover ratio shows a general downward trend, falling from 0.99 in 2017 to a low of 0.64 in 2021. This decline indicates that the company's ability to generate revenue from its equity base diminished as the equity grew faster than sales. However, a partial recovery is observed in 2022, where the ratio rose to 0.69, coinciding with a sharp increase in revenue that began to outpace the rate of equity growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?